- Home
- PLRX vs CHRS Comparison
PLRX vs CHRS Comparison
Compare PLRX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- CHRS
- Stock Information
- Founded
- PLRX 2015
- CHRS 2010
- Country
- PLRX United States
- CHRS United States
- Employees
- PLRX N/A
- CHRS N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLRX Health Care
- CHRS Health Care
- Exchange
- PLRX Nasdaq
- CHRS Nasdaq
- Market Cap
- PLRX 77.3M
- CHRS 84.2M
- IPO Year
- PLRX 2020
- CHRS 2014
- Fundamental
- Price
- PLRX $1.39
- CHRS $0.85
- Analyst Decision
- PLRX Hold
- CHRS Buy
- Analyst Count
- PLRX 10
- CHRS 3
- Target Price
- PLRX $9.79
- CHRS $4.68
- AVG Volume (30 Days)
- PLRX 1.7M
- CHRS 1.3M
- Earning Date
- PLRX 08-06-2025
- CHRS 08-07-2025
- Dividend Yield
- PLRX N/A
- CHRS N/A
- EPS Growth
- PLRX N/A
- CHRS N/A
- EPS
- PLRX N/A
- CHRS N/A
- Revenue
- PLRX N/A
- CHRS $272,251,000.00
- Revenue This Year
- PLRX N/A
- CHRS N/A
- Revenue Next Year
- PLRX N/A
- CHRS $99.43
- P/E Ratio
- PLRX N/A
- CHRS N/A
- Revenue Growth
- PLRX N/A
- CHRS 19.87
- 52 Week Low
- PLRX $1.10
- CHRS $0.66
- 52 Week High
- PLRX $16.10
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- PLRX 53.02
- CHRS 53.52
- Support Level
- PLRX $1.13
- CHRS $0.73
- Resistance Level
- PLRX $1.50
- CHRS $0.96
- Average True Range (ATR)
- PLRX 0.11
- CHRS 0.05
- MACD
- PLRX 0.03
- CHRS 0.02
- Stochastic Oscillator
- PLRX 71.23
- CHRS 53.92
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.